Takeaways From Caraco V. Novo Nordisk
The United States Supreme Court has again reversed the Federal Circuit, ruling unanimously that a generic drug manufacturer may file a counterclaim to force correction of an overbroad use code that...To view the full article, register now.
Already a subscriber? Click here to view full article